<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) progression is mediated by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSCs</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to determine if the expression of the <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> marker <z:chebi fb="1" ids="17478">aldehyde</z:chebi> dehydrogenase 1 (ALDH1) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> varies by American Joint Committee on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stage or correlates to clinical outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Primary and metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples from 96 patients were immunostained with antibodies to ALDH1 and imaged to evaluate marker expression </plain></SENT>
<SENT sid="3" pm="."><plain>The percentage of ALDH1(+) cells was correlated to clinical outcomes </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: ALDH1 was overexpressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> compared with nonneoplastic tissue </plain></SENT>
<SENT sid="5" pm="."><plain>Marker expression was highest in nonmetastatic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The loss of expression was associated with advanced stage and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>No significant correlation was found between ALDH1 expression and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, recurrence, or survival </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: ALDH1 was highly expressed in nonmetastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, but expression was lost with advancing stage </plain></SENT>
<SENT sid="9" pm="."><plain>ALDH1 could be an effective therapeutic target in early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> but not late-stage disease </plain></SENT>
<SENT sid="10" pm="."><plain>No correlation was found between ALDH1 and disease prognosis </plain></SENT>
</text></document>